Should Rx Patient Leaflets Be Labeled Like Dietary Supplements?
This article was originally published in The Pink Sheet Daily
Executive Summary
If patient medication information documents noted when they were not FDA approved, it might relieve some pre-marketing review burden on the agency, but officials worry consumers will not trust the information.
You may also be interested in...
Assurance Vs. Flexibility: Unit-Of-Use Packaging Offers Trade-Offs For Patient Leaflets
Manufacturers would have full responsibility for writing, producing, and ultimately delivering the new patient medication information document with their products, if FDA decides the industry should fully adopt the unit-of-use packaging.
Assurance Vs. Flexibility: Unit-Of-Use Packaging Offers Trade-Offs For Patient Leaflets
Manufacturers would have full responsibility for writing, producing, and ultimately delivering the new patient medication information document with their products, if FDA decides the industry should fully adopt the unit-of-use packaging.
FDA Must Maintain Oversight Role In PMI Development, Groups Urge
Advocates argue patient medication information documents could resemble advertising if FDA does not review and approve them before they are used, regardless of resources concerns.